Sunshine Heart Announces OPTIONS HF Clinical Experience

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sunshine Heart Announces OPTIONS HF Clinical Experience

EDEN PRAIRIE, Minn., May 24, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ: SSH ) announced today that its C-Pulse ® Heart Assist System was featured in a clinical presentation at the Heart Failure Association of the European Society of Cardiology Meeting, taking place from May 21 st to May 24 th in Florence, Italy.

On Saturday, May 21 st , Dr. Dimitrios Georgakopoulos, Sunshine Heart’s Chief Scientific Officer, presented data collected from a European multi-center, post-market study designed to observe the clinical outcomes of heart failure patients treated with C-Pulse.  The data demonstrated improvements in quality of life, functional capacity and cardiac remodeling with a favorable safety profile.  No patients experienced stroke or sepsis, and the driveline infection rate was 13.3% (two patients out of the fifteen participating in the study).  The data showed significant increase in Left Ventricular Ejection Fraction and significant reduction in Left Ventricular End Systolic Volume.  The data also showed a trend downward in Left Ventricular End Diastolic Volume.  These three commensurate data points have been shown to correlate with an 80% likelihood of improvement in outcomes based on the meta-analysis of several large trials studying systolic heart failure patients.¹

Sunshine Heart is excited about its recently announced clinical results especially the latest data showing the neuromodulation effect of C-Pulse.  Sunshine Heart will continue to pursue additional data in a short term study that will help clarify the path forward to the fully implantable system and a larger market potential.

¹Kramer DG et al. J Am Coll Cardiol. 2010;56:392.

About the C-Pulse ® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine ® Heart

Sunshine Heart, Inc. (Nasdaq: SSH ) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for moderate to severe heart failure patients. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe.  After terminating enrollment in its US pivotal study, COUNTER HF, Sunshine Heart will be finalizing a short term clinical strategy to begin a study of the C-Pulse Heart Assist System in the United States.  A long-term path is being developed in parallel that will focus on accelerating the development of a fully implantable system, which will be critical to driving the adoption of C-Pulse therapy.  Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management.  All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, clinical and pre-clinical study designs and activities, research and development activities, expectations regarding ultimate clinical outcomes and benefits of our products to patients, design and development of future studies, site activations, patient enrollment in studies, timing of regulatory filings and approvals, regulatory acceptance of our filings, our expectations with respect to product development and commercialization efforts, market and physician acceptance of our products, intellectual property protection, and potentially competitive product offerings. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility we may be unable to raise the funds necessary for the development and commercialization of the C-Pulse System and other risks and uncertainties described in our filings with the SEC.  We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For further information, please contact: Claudia Drayton Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4205 Investor Relations Sunshine Heart Inc. ir@sunshineheart.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 114

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 38

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 217

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 157

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 123

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 32

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading

Top 5 Most Recently Viewed Articles

Gold's Surge and Euro's Stagnation Amid Economic Shifts

Updated Category News Views 261

Gold Gains Ground Amid Geopolitical Tensions Gold prices have recently shown an impressive rise, climbing 1.9% and breaking through the resistance level of $2,600. This rally followed a significant weekly decline in prices and reflects the market's reaction to ongoing geopolitical uncertainties. The surge in gold can be traced back to several influencing factors. One of...

Continue Reading
Teachable's Innovative Rebrand and Future Learning Vision

Updated Category News Views 209

Teachable's Innovative Rebrand and Future Learning Vision Teachable, a leader in online education, proudly announces a new visual identity and a striking product vision that redefines the learning experience for everyone. As the platform continues to evolve, the changes reflect a deep commitment to meeting the needs of today’s learners and educators. A New Identity for...

Continue Reading
Functionize Elevates Software Testing with Advanced AI Solutions

Updated Category News Views 169

Functionize Enhances Automation for Software Testing Automation Innovations Reshape Testing Using Natural Language Inputs to Create Reliable Tests and Streamline Complex Processes Across Enterprises Functionize, an innovative platform leveraging AI for software test case creation, has unveiled significant enhancements to its intelligent testing solutions. The recent...

Continue Reading
Anterix Inc. Delivers Strong Fiscal Performance This Quarter

Updated Category News Views 199

Anterix Inc. Highlights Its Fiscal Progress Anterix Inc. (NASDAQ: ATEX), based in Woodlang Park, has recently revealed impressive results for its second quarter of fiscal 2026. The company has filed its Form 10-Q, reflecting the financial performance for the three and six months leading to september 30, 2025. During this quarter, Anterix provided an update on its...

Continue Reading
10X Genomics Futures Brighten with New Single Cell Products

Updated Category News Views 80

10X Genomics Holds Steady with New Innovations 10X Genomics (NASDAQ: TXG) has received a reiterated Hold rating from TD Cowen, with a price target set at $20.00. This decision follows the company's announcement of plans to launch new Single Cell (SC) products during an industry event. The innovative products aim to provide cost-effective solutions focused on reducing...

Continue Reading